Dernières nouvelles pour Acelyrin (NASDAQ:SLRN) Stock

ACELYRIN INC

Acelyrin

Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

Acelyrin Inc

Press Releases

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - OPTN, SLRN, AKYA, SHYF

News

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, SLRN, BECN on Behalf of Shareholders

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Comments

Acelyrin

Actualités

Dernières nouvelles pour Acelyrin (NASDAQ:SLRN) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL